November 05, 2026

PsA may be linked to jaw limitations

Investigators found associations between joint involvement, skin disease severity, and sleep quality in patients with psoriasis.

MDSpire News

October 30, 2026

FDA approves tildrakizumab for psoriatic arthritis

The IL-23 inhibitor gains a new indication after 2 phase 3 trials show improved joint responses versus placebo.

MDSpire News

September 25, 2026

FDA monthly preview: Key October decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

September 24, 2026

DPP-4 inhibitors may have specific autoimmune risks

Associations with dermatomyositis, bullous pemphigoid, psoriasis, and autoimmune thyroiditis differed across commonly used diabetes drug classes.

MDSpire News

August 20, 2026

Spondyloarthritis function varies by sex

Women had greater functional deterioration over 17 years, while permanent work disability did not differ significantly between sexes.

MDSpire News

August 17, 2026

Does Poor Oral Health Raise Autoimmune Disease Risk?

A study of more than 450,000 participants linked self-reported oral health issues with an increased risk of incident autoimmune diseases, though the investigators cautioned that the findings do not establish causality.

MDSpire News

August 04, 2026

Distribution Barriers May Reduce Biologic Drug Survival

A real‐world Brazilian registry suggests that challenges in biologic distribution were associated with treatment interruption, particularly among therapies requiring more frequent dosing.

MDSpire News

July 23, 2026

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

MDSpire News

July 22, 2026

Ixekizumab May Improve Early Response After Secukinumab Failure

A real-world cohort found faster early skin responses with ixekizumab than with guselkumab or ustekinumab following secukinumab treatment failure, while all three biologics demonstrated favorable safety.

MDSpire News

July 09, 2026

Mental Health May Impact Dermatologic Quality of Life

Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.

MDSpire News